Reirradiation and lomustine in patients with relapsed high-grade gliomas

Zweitbestrahlung bei malignen Gliomen: eine retrospektive Auswertung

“…To assess the exact impact of re-irradiation on TTP and overall survival, prospective trials with larger patient numbers are warranted. Interestingly, another study comparing the effect of reresection, re-irradiation and chemotherapy with CCNU reported different results [20]: whereas overall survival from onset of re-treatment was 13.7 months and therefore similar to our results, there was no difference in survival between patients who underwent surgery and those who did not. We cannot be sure what the reason for this might be, although the authors of the study were surprised by the relatively long median survival of all patients.…”

Hypofractionated reirradiation for recurrent malignant glioma

“…In this regard, several different modalities of percutaneous radiotherapy or brachytherapy for retreatment of glioblastomas have been investigated. In general, all data consistently show that, whenever employed cautiously, reirradiation is feasible and most likely prolongs survival [1,4,7,8,11,13,14,21,24,34,35,38,[40][41][42].…”

“…Comparison of overall survival and toxicity of the chosen treatment with results of different approaches using external-beam radiotherapy for reirradiation reported over the last years [1,4,8,9,11,22,25,35,36,[41][42][43] certainly remains difficult because of the variation in target definition, treatment technique, tumor volume, concomitant chemotherapy, and initial patient characteristics. However, considering the large median PTV of 50 ml and the high number of glioblastoma included, this is comparable to the earlier results.…”

Chemoradiotherapy: Radiation Total Dose and Fractionation

“…Some investigators explored the association of conventional or hypo-fractionated radiotherapy with lomustine (CCNU) [ 166 ] concurrent to 34.5 Gy at 1.5 Gy for fraction, with CDDP [ 167 ] concurrent to hypo-fractionated RT (35-42 Gy at 3.5-6 Gy for fraction), or with paclitaxel receiving 18-36 Gy at 4-9 Gy/fr [ 118 ], or with topotecan treated with 30 Gy in 6 fractions [ 168 ]. The median overall survival ranged from 7 in the case of paclitaxel to 13.7 months when radiotherapy was concurrent to lomustine and CDDP.…”